Evidence map›Paper›PMID 33584817›Full record

ArticleFrontiers in genetics2020

A Seven-Long Non-coding RNA Signature Improves Prognosis Prediction of Lung Adenocarcinoma: An Integrated Competing Endogenous RNA Network Analysis.

Rang Li, Kedong Han, Dehua Xu, Xiaolin Chen, Shujin Lan, Yuanjun Liao, Shengnan Sun, Shaoqi Rao

Abstract read
In one paragraph

Article in Frontiers in genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rang LiInstitute of Medical Systems Biology, School of Public Health, Guangdong Medical University, Dongguan, China.
Kedong HanDepartment of Cardiology, Maoming People's Hospital, Maoming, China.
Dehua XuInstitute of Medical Systems Biology, School of Public Health, Guangdong Medical University, Dongguan, China.
Xiaolin ChenInstitute of Medical Systems Biology, School of Public Health, Guangdong Medical University, Dongguan, China.
Shujin LanInstitute of Medical Systems Biology, School of Public Health, Guangdong Medical University, Dongguan, China.
Yuanjun LiaoInstitute of Medical Systems Biology, School of Public Health, Guangdong Medical University, Dongguan, China.
Shengnan SunInstitute of Medical Systems Biology, School of Public Health, Guangdong Medical University, Dongguan, China.
Shaoqi RaoInstitute of Medical Systems Biology, School of Public Health, Guangdong Medical University, Dongguan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early and precise prediction is an important way to reduce the poor prognosis of lung adenocarcinoma (LUAD) patients. Nevertheless, the widely used tumor, node, and metastasis (TNM) staging system based on anatomical information only often could not achieve adequate performance on foreseeing the prognosis of LUAD patients. This study thus aimed to examine whether the long non-coding RNAs (lncRNAs), known highly involved in the tumorigenesis of LUAD through the competing endogenous RNAs (ceRNAs) mechanism, could provide additional information to improve prognosis prediction of LUAD patients. To prove the hypothesis, a dataset consisting of both RNA sequencing data and clinical pathological data, obtained from The Cancer Genome Atlas (TCGA) database, was analyzed. Then, differentially expressed RNAs (DElncRNAs, DEmiRNAs, and DEmRNAs) were identified and a lncRNA-miRNA-mRNA ceRNA network was constructed based on those differentially expressed RNAs. Functional enrichment analysis revealed that this ceRNA network was highly enriched in some cancer-associated signaling pathways. Next, lasso-Cox model was run 1,000 times to recognize the potential survival-related combinations of the candidate lncRNAs in the ceRNA network, followed by the "best subset selection" to further optimize these lncRNA-based combinations, and a seven-lncRNA prognostic signature with the best performance was determined. Based on the median risk score, LUAD patients could be well distinguished into high-/low-risk subgroups. The Kaplan-Meier survival curve showed that LUAD patients in the high-risk group had significantly shorter overall survival than those in the low-risk group (log-rank test

Indexed as

ceRNA networklncRNAlung adenocarcinomamolecular signature for survivalprognosis

Identifiers

PMID33584817
PMCPMC7876394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.